Abstract
June 1994,378 patients (pts) with ABC, all of whom had failed prior antioestrogen treatment, were randomized to one of two doses of A (1 mg or 10 mg oral once daily) or to MA (40 mg x 4 times daily). Patients were equally distributed between the three treatment arms for major prognostic variables such as prior hormonal treatment, hormone receptor status, prior chemotherapy, performance status, and site of disease. After a median follow-up of 6.1 months, intention to treat analyses were performed on response rates using logistic regression and an analysis to time to progression (TTP), time to treatment failure (TTF) and survival using the Cox proportional hazards model:
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
